Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- Rebetron (interferon alfa-2b / ribavirin)
- thiotepa
Interactions between your drugs
thiotepa interferon alfa-2b
Applies to: thiotepa, Rebetron (interferon alfa-2b / ribavirin)
Using thiotepa together with interferon alfa-2b or other chemotherapy drugs may increase the risk of side effects, especially those that affect the bone marrow or gastrointestinal tract. You may experience a greater number or more severe side effects such as nausea; vomiting; diarrhea; loss of appetite; mouth sores; abdominal pain; delayed wound healing; and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. You should seek medical attention if you develop paleness, fatigue, dizziness, fainting, unusual bruising or bleeding, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. You may need a dose adjustment or more frequent monitoring by your doctor to safely use these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
ribavirin food
Applies to: Rebetron (interferon alfa-2b / ribavirin)
Food can enhance the levels of ribavirin in your body. Ribavirin should be taken with food or just after eating. This will make it easier for your body to absorb the medication. Do not take it on an empty stomach. Swallow the tablet or capsule whole.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
AccessPak for HIV PEP Basic
AccessPak for HIV PEP Basic is used for HIV Infection, nonoccupational exposure, occupational ...
AccessPak for HIV PEP Expanded with Kaletra
AccessPak for HIV PEP Expanded with Kaletra is used for HIV Infection
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
AccessPak for HIV PEP Expanded with Viracept
AccessPak for HIV PEP Expanded with Viracept is used for HIV Infection
Biktarvy
Biktarvy is a complete HIV-1 treatment in a once-a-day single tablet containing three antiviral ...
Cabenuva
Cabenuva (cabotegravir and rilpivirine) injections are a long-acting HIV treatment used to keep HIV ...
Cimduo
Cimduo (lamivudine and tenofovir disoproxil fumarate) is used to treat HIV infection. Includes ...
Complera
Complera (emtricitabine, rilpivirine, and tenofovir) is used to treat HIV infection. Includes ...
Delstrigo
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) is a combination, oral, antiviral ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.